Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer

[snoraste]

I know Guardian360 is being recommended on this forum for genetic profiling. I don't know enough about genetic testing to speak intelligently about this article. However, it's worth a pause and a discussion with your geneticist/MO if Guardian360 is the right sequencing platform. Maybe people who know a lot more than me can comment on it.

"TAKE-HOME MESSAGE

This study compared a commercially available sequencing test (Guardant360) with an academic research prostate-specific sequencing assay (Vancouver) using circulating tumor DNA from 24 patients with metastatic prostate cancer. In most cases (94%), somatic mutations with allele fraction >1% were detected by both assays. Similarly, amplifications and mutations of the AR gene were detected with high concordance in 14 patients. In contrast, several clinically relevant DNA repair gene alterations (eg, germline BRCA2, ATM mutations, BRCA2 stop gain reversal mutation) not detected by Guardant360 were identified by the research assay.

In this study, concordance for somatic mutations with allele fraction >1% was very high, but low allele frequency mutations were often missed, suggesting that NGS assays may be further optimized for clinical utility in prostate cancer."

practiceupdate.com/C/85533/...